Don’t worry if you missed this year’s conference as we recorded some of the brilliant sessions which you can watch below.
Paul Coia interviews…
Correction: The details on Slide 13 of the presentation should be switched between Blade Therapeutics and Q-State Biosciences. Blade Therapeutics pre-clinical studies are on compound BLD-2736, and their compound BLD-2184 is on track to enter a Phase 1 study in 2022. Please see Blade Therapeutic’s press release: https://www.blademed.com/news/Oct-07-2021/
It Works for Me